Abstract
Since their introduction in the late 1980s, proton pump inhibitors have demonstrated gastric acid suppression superior to that of histamine H2-receptor blockers. Proton pump inhibitors have enabled improved treatment of various acid-peptic disorders, including gastroesophageal reflux disease, peptic ulcer disease, and nonsteroidal antiinflammatory drug-induced gastropathy. Proton pump inhibitors have minimal side effects and few significant drug interactions, and they are generally considered safe for long-term treatment. The proton pump inhibitors omeprazole, lansoprazole, rabeprazole, and the recently approved esomeprazole appear to have similar efficacy.
MeSH terms
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Benzimidazoles / pharmacokinetics
-
Benzimidazoles / pharmacology
-
Benzimidazoles / therapeutic use
-
Drug Interactions
-
Esomeprazole
-
Gastroesophageal Reflux / drug therapy*
-
Humans
-
Lansoprazole
-
Omeprazole / analogs & derivatives*
-
Omeprazole / pharmacokinetics
-
Omeprazole / pharmacology
-
Omeprazole / therapeutic use
-
Pantoprazole
-
Peptic Ulcer / drug therapy
-
Proton Pump Inhibitors*
-
Rabeprazole
-
Sulfoxides / pharmacokinetics
-
Sulfoxides / therapeutic use
Substances
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Benzimidazoles
-
Proton Pump Inhibitors
-
Sulfoxides
-
Lansoprazole
-
Rabeprazole
-
Pantoprazole
-
Omeprazole
-
Esomeprazole